Prostaglandin E2 Augments IL-10 Signaling and Function
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
In inflamed joints of rheumatoid arthritis, PGE2 is highly expressed, and IL-10 and IL-6 are also abundant. PGE2 is a well-known activator of the cAMP signaling pathway, and there is functional cross-talk between cAMP signaling and the Jak-STAT signaling pathway. In this study, we evaluated the modulating effect of PGE2 on STAT signaling and its biological function induced by IL-10 and IL-6, and elucidated its mechanism in THP-1 cells. STAT phosphorylation was determined by Western blot, and gene expression was analyzed using real-time PCR. Pretreatment with PGE2 significantly augmented IL-10-induced STAT3 and STAT1 phosphorylation, as well as suppressors of cytokine signaling 3 (SOCS3) and IL-1R antagonist gene expression. In contrast, PGE2 suppressed IL-6-induced phosphorylation of STAT3 and STAT1. These PGE2-induced modulating effects were largely reversed by actinomycin D. Pretreatment with dibutyryl cAMP augmented IL-10-induced, but did not change IL-6-induced STAT3 phosphorylation. Misoprostol, an EP2/3/4 agonist, and butaprost, an EP2 agonist, augmented IL-10-induced STAT3 phosphorylation and SOCS3 gene expression, but sulprostone, an EP1/3 agonist, had no effect. H89, a protein kinase A inhibitor, and LY294002, a PI3K inhibitor, diminished PGE2-mediated augmentation of IL-10-induced STAT3 phosphorylation. In this study, we found that PGE2 selectively regulates cytokine signaling via increased intracellular cAMP levels and de novo gene expression, and these modulating effects may be mediated through EP2 or EP4 receptors. PGE2 may modulate immune responses by alteration of cytokine signaling in THP-1 cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Niemand, C., Nimmesgern, A., Haan, S., Fischer, P., Schaper, F., Rossaint, R., Heinrich, P. C., & Müller-Newen, G. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.6.3263 · Cited by 357
FISCHER, P., LEHMANN, U., SOBOTA, R. M., SCHMITZ, J., NIEMAND, C., LINNEMANN, S., HAAN, S., BEHRMANN, I., YOSHIMURA, A., JOHNSTON, J. A., et al. (2004) · Biochemical Journal · doi:10.1042/bj20030893 · Cited by 72 · cited 1×
“Because SOCS3 is a major feedback inhibitor of IL-6-induced STAT signaling (20, 24, 25), we suspected that SOCS3 may be involved in the PGE2-mediated inhibition of IL-6-induced STAT3 activation.”
Background
Cited by
SOCS proteins, cytokine signalling and immune regulation
Yoshimura, A., Naka, T., & Kubo, M. (2007) · Nature Reviews Immunology · doi:10.1038/nri2093 · Cited by 1,580
“However, there is a possibility that SOCS3 itself is a mediator of the anti-inflammatory response, because SOCS3 protein levels are upregulated by IL-10, as well as by prostaglandin E 2 (another potent anti-inflammatory mediator) through the cAMP pathwa”
BackgroundWoodward, D. F., Jones, R. L., & Narumiya, S. (2011) · Pharmacological Reviews · doi:10.1124/pr.110.003517 · Cited by 443
Wang, Z., Brandt, S., Medeiros, A., Wang, S., Wu, H., Dent, A., & Serezani, C. H. (2015) · PLOS ONE · doi:10.1371/journal.pone.0115855 · Cited by 169
“PGE2 is known to control STAT3 activation and expression [44–47].”
BackgroundProstaglandin receptor EP2 in the crosshairs of anti-inflammation, anti-cancer, and neuroprotection
Jiang, J., & Dingledine, R. (2013) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2013.05.003 · Cited by 166
“Thus PGE2 acts as an immune modulator rather than a simple pro-inflammatory molecule [41].”
Al-Taei, S., Salimu, J., Spary, L. K., Clayton, A., Lester, J. F., & Tabi, Z. (2017) · OncoImmunology · doi:10.1080/2162402x.2016.1268308 · Cited by 17
“may favor CREB binding, similar to what has been shown in the human myeloid THP cell line.(40) We are currently investigating”
Method
Metadata
- Authors
- Cheon, H., Rho, Y. H., Choi, S. J., Lee, Y. H., Song, G. G., Sohn, J., Won, N. H., & Ji, J. D.
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2006-07
- Volume
- 177
- Issue
- 2
- Pages
- 1092-1100
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W2120142178
- Cited by
- 100
- References
- 2
- FWCI
- 2.95
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.